Clinical Trials Directory

Trials / Completed

CompletedNCT01857713

Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device

A Multi-Center, Non-Randomized, Prospective Study of the Reza Band™ Upper Esophageal Sphincter (UES) Assist Device for the Treatment of Esophagopharyngeal Reflux

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
95 (actual)
Sponsor
Somna Therapeutics, L.L.C. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to determine the safety and effectiveness of non-invasive Reza Band UES Assist Device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing).

Detailed description

The purpose of the study is to determine the safety and effectiveness of non-invasive Reza Band UES Assist Device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing). Reza Band is to be worn when sleeping. The patient will put the Reza Band on at bedtime and take it off upon waking. This is a prospective, non-randomized, open label, multicenter study designed to assess the safety and effectiveness of the Reza Band. At up to 5 investigational sites, up to 100 subjects will be enrolled. The primary effectiveness endpoint is to be evaluated by the Reflux Symptom Index (RSI). Success is defined as \>25% reduction in the RSI at the last follow-up, as compared to the baseline RSI. The RSI is a validated nine-item patient-administered outcome questionnaire designed to document symptoms and severity. Patients are asked to rate how nine problems have affected them on a scale of 0 (no problem) to 5 (severe problem), with a maximum total score of 45. All adverse reactions being reported will be evaluated with the frequency and percent of subjects of each reaction being summarized by severity and by relationship to the Reza Band. Since some subjects may report the same event several times (e.g., redness), the first occurrence of the worst reported case of the event will be used for the purpose of analysis. The incidence of site reactions, including laryngospasm, choking, pain, cough and hoarseness will be summarized. Exact 95% confidence intervals for the incidence rate of site reactions will be presented.

Conditions

Interventions

TypeNameDescription
DEVICEReza Band UES Assist DeviceDevice is worn by patient to reduce or eliminate laryngopharyngeal reflux

Timeline

Start date
2013-04-01
Primary completion
2013-09-01
Completion
2013-09-01
First posted
2013-05-20
Last updated
2015-06-19
Results posted
2015-05-21

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01857713. Inclusion in this directory is not an endorsement.